Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease

A pilot double-blind randomized controlled trial

Yunes Panahi, Parisa Kianpour, Reza Mohtashami, Stephen Atkin, Alexandra E. Butler, Ramezan Jafari, Roghayeh Badeli, Amirhossein Sahebkar

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide and is potentially treatable, though there are few therapeutic agents available. Artichoke leaf extract (ALE) has shown potential as a hepatoprotective agent. This study sought to determine if ALE had therapeutic utility in patients with established NAFLD. In this randomized double-blind placebo-controlled parallel-group trial, 100 subjects with ultrasound-diagnosed NAFLD were randomized to either ALE 600 mg daily or placebo for a 2-month period. NAFLD response was assessed by liver ultrasound and serological markers including the aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio and AST to platelet ratio index (APRI) score. Ninety patients completed the study (49 ALE and 41 placebo) with no side effects reported. ALE treatment compared with placebo: Doppler sonography showed increased hepatic vein flow (p <.001), reduced portal vein diameter (p <.001) and liver size (p <.001), reduction in serum ALT (p <.001) and AST (p <.001) levels, improvement in AST/ALT ratio and APRI scores (p <.01), and reduction in total bilirubin. ALE supplementation reduced total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and triglyceride concentrations (p =.01). This study has shown beneficial effects of ALE supplementation on both ultrasound liver parameters and liver serum parameters (ALT, AST, APRI ratio, and total bilirubin) in patients with NAFLD.

Original languageEnglish
Pages (from-to)1382-1387
Number of pages6
JournalPhytotherapy Research
Volume32
Issue number7
DOIs
Publication statusPublished - 1 Jul 2018

Fingerprint

Cynara scolymus
Randomized Controlled Trials
Aspartate Aminotransferases
Alanine Transaminase
Placebos
Blood Platelets
Liver
Bilirubin
Doppler Ultrasonography
Hepatic Veins
Portal Vein
Non-alcoholic Fatty Liver Disease
Serum
LDL Cholesterol
HDL Cholesterol
Liver Diseases
Chronic Disease
Therapeutics
Cholesterol

Keywords

  • artichoke leaf extract (ALE)
  • non-alcoholic fatty liver disease (NAFLD)
  • phytochemical

ASJC Scopus subject areas

  • Pharmacology

Cite this

Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease : A pilot double-blind randomized controlled trial. / Panahi, Yunes; Kianpour, Parisa; Mohtashami, Reza; Atkin, Stephen; Butler, Alexandra E.; Jafari, Ramezan; Badeli, Roghayeh; Sahebkar, Amirhossein.

In: Phytotherapy Research, Vol. 32, No. 7, 01.07.2018, p. 1382-1387.

Research output: Contribution to journalArticle

Panahi, Y, Kianpour, P, Mohtashami, R, Atkin, S, Butler, AE, Jafari, R, Badeli, R & Sahebkar, A 2018, 'Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: A pilot double-blind randomized controlled trial', Phytotherapy Research, vol. 32, no. 7, pp. 1382-1387. https://doi.org/10.1002/ptr.6073
Panahi, Yunes ; Kianpour, Parisa ; Mohtashami, Reza ; Atkin, Stephen ; Butler, Alexandra E. ; Jafari, Ramezan ; Badeli, Roghayeh ; Sahebkar, Amirhossein. / Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease : A pilot double-blind randomized controlled trial. In: Phytotherapy Research. 2018 ; Vol. 32, No. 7. pp. 1382-1387.
@article{2b16430fa1ec427180938c5dac65d697,
title = "Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: A pilot double-blind randomized controlled trial",
abstract = "Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide and is potentially treatable, though there are few therapeutic agents available. Artichoke leaf extract (ALE) has shown potential as a hepatoprotective agent. This study sought to determine if ALE had therapeutic utility in patients with established NAFLD. In this randomized double-blind placebo-controlled parallel-group trial, 100 subjects with ultrasound-diagnosed NAFLD were randomized to either ALE 600 mg daily or placebo for a 2-month period. NAFLD response was assessed by liver ultrasound and serological markers including the aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio and AST to platelet ratio index (APRI) score. Ninety patients completed the study (49 ALE and 41 placebo) with no side effects reported. ALE treatment compared with placebo: Doppler sonography showed increased hepatic vein flow (p <.001), reduced portal vein diameter (p <.001) and liver size (p <.001), reduction in serum ALT (p <.001) and AST (p <.001) levels, improvement in AST/ALT ratio and APRI scores (p <.01), and reduction in total bilirubin. ALE supplementation reduced total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and triglyceride concentrations (p =.01). This study has shown beneficial effects of ALE supplementation on both ultrasound liver parameters and liver serum parameters (ALT, AST, APRI ratio, and total bilirubin) in patients with NAFLD.",
keywords = "artichoke leaf extract (ALE), non-alcoholic fatty liver disease (NAFLD), phytochemical",
author = "Yunes Panahi and Parisa Kianpour and Reza Mohtashami and Stephen Atkin and Butler, {Alexandra E.} and Ramezan Jafari and Roghayeh Badeli and Amirhossein Sahebkar",
year = "2018",
month = "7",
day = "1",
doi = "10.1002/ptr.6073",
language = "English",
volume = "32",
pages = "1382--1387",
journal = "Phytotherapy Research",
issn = "0951-418X",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease

T2 - A pilot double-blind randomized controlled trial

AU - Panahi, Yunes

AU - Kianpour, Parisa

AU - Mohtashami, Reza

AU - Atkin, Stephen

AU - Butler, Alexandra E.

AU - Jafari, Ramezan

AU - Badeli, Roghayeh

AU - Sahebkar, Amirhossein

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide and is potentially treatable, though there are few therapeutic agents available. Artichoke leaf extract (ALE) has shown potential as a hepatoprotective agent. This study sought to determine if ALE had therapeutic utility in patients with established NAFLD. In this randomized double-blind placebo-controlled parallel-group trial, 100 subjects with ultrasound-diagnosed NAFLD were randomized to either ALE 600 mg daily or placebo for a 2-month period. NAFLD response was assessed by liver ultrasound and serological markers including the aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio and AST to platelet ratio index (APRI) score. Ninety patients completed the study (49 ALE and 41 placebo) with no side effects reported. ALE treatment compared with placebo: Doppler sonography showed increased hepatic vein flow (p <.001), reduced portal vein diameter (p <.001) and liver size (p <.001), reduction in serum ALT (p <.001) and AST (p <.001) levels, improvement in AST/ALT ratio and APRI scores (p <.01), and reduction in total bilirubin. ALE supplementation reduced total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and triglyceride concentrations (p =.01). This study has shown beneficial effects of ALE supplementation on both ultrasound liver parameters and liver serum parameters (ALT, AST, APRI ratio, and total bilirubin) in patients with NAFLD.

AB - Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide and is potentially treatable, though there are few therapeutic agents available. Artichoke leaf extract (ALE) has shown potential as a hepatoprotective agent. This study sought to determine if ALE had therapeutic utility in patients with established NAFLD. In this randomized double-blind placebo-controlled parallel-group trial, 100 subjects with ultrasound-diagnosed NAFLD were randomized to either ALE 600 mg daily or placebo for a 2-month period. NAFLD response was assessed by liver ultrasound and serological markers including the aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio and AST to platelet ratio index (APRI) score. Ninety patients completed the study (49 ALE and 41 placebo) with no side effects reported. ALE treatment compared with placebo: Doppler sonography showed increased hepatic vein flow (p <.001), reduced portal vein diameter (p <.001) and liver size (p <.001), reduction in serum ALT (p <.001) and AST (p <.001) levels, improvement in AST/ALT ratio and APRI scores (p <.01), and reduction in total bilirubin. ALE supplementation reduced total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and triglyceride concentrations (p =.01). This study has shown beneficial effects of ALE supplementation on both ultrasound liver parameters and liver serum parameters (ALT, AST, APRI ratio, and total bilirubin) in patients with NAFLD.

KW - artichoke leaf extract (ALE)

KW - non-alcoholic fatty liver disease (NAFLD)

KW - phytochemical

UR - http://www.scopus.com/inward/record.url?scp=85049538595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049538595&partnerID=8YFLogxK

U2 - 10.1002/ptr.6073

DO - 10.1002/ptr.6073

M3 - Article

VL - 32

SP - 1382

EP - 1387

JO - Phytotherapy Research

JF - Phytotherapy Research

SN - 0951-418X

IS - 7

ER -